Ke Liu, MD, PhD

Independent Director

Ke Liu, MD, PhD, is Chief Development Officer of Marengo Therapeutics. Ke has over 20 years of experience in the field of oncology, immuno-oncology, and cell and gene therapy, most recently serving as Senior Vice President and leading key regulatory activities at Sana Biotechnology. Prior to Sana, he spent more than 17 years working at the U.S. Food and Drug Administration (FDA) where he held leadership roles at the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and the Oncology Center of Excellence (OCE). Ke has made major contributions to the field of oncology and led the clinical evaluations and approvals of key first-in-class cancer therapeutics over the past decade, including checkpoint inhibitors, chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) modified T cells, genome-edited products, neoantigen-based therapies, adoptive T cell therapies, oncolytic viral therapy, dendritic cell therapy, and combinations of these immune-oncologic therapeutics with checkpoint inhibitors and other agents.

Ke received his MD from Henan Medical University in China and his PhD in molecular biology from Cornell University. He completed his internal medicine internship and residency at Albert Einstein College of Medicine, his medical oncology fellowship at the National Cancer Institute (NCI), and additional cancer immunotherapy training at the NCI’s Surgery Branch. Ke is an internist and medical oncologist certified by the American Board of Internal Medicine.